Detalhe da pesquisa
1.
The hVps34-SGK3 pathway alleviates sustained PI3K/Akt inhibition by stimulating mTORC1 and tumour growth.
EMBO J
; 35(17): 1902-22, 2016 09 01.
Artigo
Inglês
| MEDLINE | ID: mdl-27481935
2.
The hVps34-SGK3 pathway alleviates sustained PI3K/Akt inhibition by stimulating mTORC1 and tumour growth.
EMBO J
; 35(20): 2263, 2016 10 17.
Artigo
Inglês
| MEDLINE | ID: mdl-27798145
3.
Characterization of VPS34-IN1, a selective inhibitor of Vps34, reveals that the phosphatidylinositol 3-phosphate-binding SGK3 protein kinase is a downstream target of class III phosphoinositide 3-kinase.
Biochem J
; 463(3): 413-27, 2014 Nov 01.
Artigo
Inglês
| MEDLINE | ID: mdl-25177796
4.
Elevated SGK1 predicts resistance of breast cancer cells to Akt inhibitors.
Biochem J
; 452(3): 499-508, 2013 Jun 15.
Artigo
Inglês
| MEDLINE | ID: mdl-23581296
5.
Osimertinib + Savolitinib to Overcome Acquired MET-Mediated Resistance in Epidermal Growth Factor Receptor-Mutated, MET-Amplified Non-Small Cell Lung Cancer: TATTON.
Cancer Discov
; 13(1): 98-113, 2023 01 09.
Artigo
Inglês
| MEDLINE | ID: mdl-36264123
6.
ERK5 is required for VEGF-mediated survival and tubular morphogenesis of primary human microvascular endothelial cells.
J Cell Sci
; 123(Pt 18): 3189-200, 2010 Sep 15.
Artigo
Inglês
| MEDLINE | ID: mdl-20736307
7.
Structure-activity relationship of a series of non peptidic RGD integrin antagonists targeting α5ß1: part 1.
Bioorg Med Chem Lett
; 22(12): 4111-6, 2012 Jun 15.
Artigo
Inglês
| MEDLINE | ID: mdl-22575869
8.
Structure-activity relationship of a series of non peptidic RGD integrin antagonists targeting α5ß1: part 2.
Bioorg Med Chem Lett
; 22(12): 4117-21, 2012 Jun 15.
Artigo
Inglês
| MEDLINE | ID: mdl-22572578
9.
Brain metastatic outgrowth and osimertinib resistance are potentiated by RhoA in EGFR-mutant lung cancer.
Nat Commun
; 13(1): 7690, 2022 12 12.
Artigo
Inglês
| MEDLINE | ID: mdl-36509758
10.
Shear stress, tip cells and regulators of endothelial migration.
Biochem Soc Trans
; 39(6): 1571-5, 2011 Dec.
Artigo
Inglês
| MEDLINE | ID: mdl-22103489
11.
Inhibitors of the tyrosine kinase EphB4. Part 4: Discovery and optimization of a benzylic alcohol series.
Bioorg Med Chem Lett
; 21(8): 2207-11, 2011 Apr 15.
Artigo
Inglês
| MEDLINE | ID: mdl-21441027
12.
Kinase drug discovery 20 years after imatinib: progress and future directions.
Nat Rev Drug Discov
; 20(7): 551-569, 2021 07.
Artigo
Inglês
| MEDLINE | ID: mdl-34002056
13.
Potent and Selective Inhibitors of the Epidermal Growth Factor Receptor to Overcome C797S-Mediated Resistance.
J Med Chem
; 64(18): 13704-13718, 2021 09 23.
Artigo
Inglês
| MEDLINE | ID: mdl-34491761
14.
Preclinical Comparison of the Blood-brain barrier Permeability of Osimertinib with Other EGFR TKIs.
Clin Cancer Res
; 27(1): 189-201, 2021 01 01.
Artigo
Inglês
| MEDLINE | ID: mdl-33028591
15.
Oncogenic switch and single-agent MET inhibitor sensitivity in a subset of EGFR-mutant lung cancer.
Sci Transl Med
; 13(609): eabb3738, 2021 Sep.
Artigo
Inglês
| MEDLINE | ID: mdl-34516823
16.
Inhibitors of the tyrosine kinase EphB4. Part 3: identification of non-benzodioxole-based kinase inhibitors.
Bioorg Med Chem Lett
; 20(21): 6242-5, 2010 Nov 01.
Artigo
Inglês
| MEDLINE | ID: mdl-20850301
17.
Osimertinib, an Irreversible Next-Generation EGFR Tyrosine Kinase Inhibitor, Exerts Antitumor Activity in Various Preclinical NSCLC Models Harboring the Uncommon EGFR Mutations G719X or L861Q or S768I.
Mol Cancer Ther
; 19(11): 2298-2307, 2020 11.
Artigo
Inglês
| MEDLINE | ID: mdl-32943544
18.
Efficacy of osimertinib against EGFRvIII+ glioblastoma.
Oncotarget
; 11(22): 2074-2082, 2020 Jun 02.
Artigo
Inglês
| MEDLINE | ID: mdl-32547705
19.
Drug Sensitivity and Allele Specificity of First-Line Osimertinib Resistance EGFR Mutations.
Cancer Res
; 80(10): 2017-2030, 2020 05 15.
Artigo
Inglês
| MEDLINE | ID: mdl-32193290
20.
ERK5 and the regulation of endothelial cell function.
Biochem Soc Trans
; 37(Pt 6): 1254-9, 2009 Dec.
Artigo
Inglês
| MEDLINE | ID: mdl-19909257